טוען...
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme
Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM). Caelyx (liposomal doxorubicin) has established activity in a broad range of tumors but has not been extensively evaluated in the treatment of GBM. Phase 1 data suggest that temozolomide and Caelyx can...
שמור ב:
| Main Authors: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Duke University Press
2004
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1871967/ https://ncbi.nlm.nih.gov/pubmed/14769139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/S1152851703000188 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|